Division of Endocrinology and Metabolism, Department of Internal Medicine, Taipei Tzu-Chi Hospital, Buddhist Tzu-Chi Medical Foundation, New Taipei City.
School of Medicine, Tzu Chi University, Hualien.
J Hypertens. 2020 Apr;38(4):745-754. doi: 10.1097/HJH.0000000000002300.
The association between hyperaldosteronism and autoimmune disorders has been postulated. However, long-term incidence of a variety of new-onset autoimmune diseases (NOAD) among patients with primary aldosteronism has not been well investigated.
From Taiwan's National Health Insurance Research Database with a 23-million population insurance registry, the identification of primary aldosteronism, essential hypertension and NOAD as well as all-cause mortality were ascertained by a validated algorithm.
From 1997 to 2009, 2319 primary aldosteronism patients without previously autoimmune disease were identified and propensity score-matched with 9276 patients with essential hypertension. Among those primary aldosteronism patients, 806 patients with aldosterone-producing adenomas (APA) were identified and matched with 3224 essential hypertension controls. NOAD incidence is augmented in primary aldosteronism patients compared with its matched essential hypertension (hazard ratio 3.82, P < 0.001, versus essential hypertension). Furthermore, NOAD incidence is also higher in APA patients compared with its matched essential hypertension (hazard ratio = 2.96, P < 0.001, versus essential hypertension). However, after a mean 8.9 years of follow-up, primary aldosteronism patients who underwent adrenalectomy (hazard ratio = 3.10, P < 0.001, versus essential hypertension) and took mineralocorticoid receptor antagonist (MRA) still had increased NOAD incidence (hazard ratio = 4.04, P < 0.001, versus essential hypertension).
Primary aldosteronism patients had an augmented risk for a variety of incident NOAD and all-cause of mortality, compared with matched essential hypertension controls. Notably, the risk of incident NOAD remained increased in patients treated by adrenalectomy or MRA compared with matched essential hypertension controls. This observation supports the theory of primary aldosteronism being associated with a higher risk of multiple autoimmune diseases.
醛固酮增多症与自身免疫性疾病之间存在关联。然而,原发性醛固酮增多症患者新发多种自身免疫性疾病(NOAD)的长期发病率尚未得到很好的研究。
我们从台湾全民健康保险研究数据库中筛选出 2300 万名被保险人的保险登记数据,通过验证过的算法确定原发性醛固酮增多症、原发性高血压和新发自身免疫性疾病以及全因死亡率。
1997 年至 2009 年,我们确定了 2319 例无先前自身免疫性疾病的原发性醛固酮增多症患者,并与 9276 例原发性高血压患者进行了倾向评分匹配。在这些原发性醛固酮增多症患者中,我们确定了 806 例醛固酮瘤(APA)患者,并与 3224 例原发性高血压对照进行了匹配。与匹配的原发性高血压相比,原发性醛固酮增多症患者的新发自身免疫性疾病发病率增加(风险比 3.82,P<0.001)。此外,与匹配的原发性高血压相比,APA 患者的新发自身免疫性疾病发病率也更高(风险比=2.96,P<0.001)。然而,在平均 8.9 年的随访后,接受肾上腺切除术(风险比=3.10,P<0.001)和使用盐皮质激素受体拮抗剂(MRA)的原发性醛固酮增多症患者新发自身免疫性疾病的发病率仍有所增加(风险比=4.04,P<0.001)。
与匹配的原发性高血压对照组相比,原发性醛固酮增多症患者新发多种自身免疫性疾病和全因死亡率的风险增加。值得注意的是,与匹配的原发性高血压对照组相比,接受肾上腺切除术或 MRA 治疗的患者新发自身免疫性疾病的风险仍然增加。这一观察结果支持原发性醛固酮增多症与多种自身免疫性疾病风险增加有关的理论。